TNXP (Tonix Pharmaceuticals Holding) Research & Development: $55.26 Mil (TTM As of Mar. 2026)


TNXP Tonix Pharmaceuticals Holding Corp TNXP
41 GF Score
Price $13.11
GF Value $1.75
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Research & Development?

Tonix Pharmaceuticals Holding TNXP +10.54% 41 Research & Development is $55.26 Mil as of Mar. 2026. GuruFocus rates TNXP with a GF Score™ of 41/100 and a GF Value™ of $1.75 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Tonix Pharmaceuticals Holding's Research & Development for the three months ended in Mar. 2026 was $18.21 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $55.26 Mil.

Tonix Pharmaceuticals Holding  (NAS:TNXP) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Tonix Pharmaceuticals Holding Research & Development Related Terms

Tonix Pharmaceuticals Holding Research & Development Historical Data

* Premium members only.

The historical data trend for Tonix Pharmaceuticals Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Research & Development Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.84 81.88 86.66 39.97 44.49

Tonix Pharmaceuticals Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.44 10.82 9.29 16.94 18.21
TNXP
41GF Score
Tonix Pharmaceuticals Holding Corp TNXP
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $55.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $55.26 Mil mean?
Tonix Pharmaceuticals Holding (TNXP) has a Research & Development of $55.26 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Tonix Pharmaceuticals Holding and its competitors.
Is Tonix Pharmaceuticals Holding's Research & Development too high?
Tonix Pharmaceuticals Holding's current Research & Development is $55.26 Mil. Overall, Tonix Pharmaceuticals Holding has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tonix Pharmaceuticals Holding's Research & Development compare to UNCY and ENLV?
Tonix Pharmaceuticals Holding's Research & Development of $55.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Tonix Pharmaceuticals Holding and its competitors. Tonix Pharmaceuticals Holding's current Research & Development is $55.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tonix Pharmaceuticals Holding stock overvalued right now?
Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding (TNXP) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.75, compared to a current price of $13.11 — trading 649.1% above its estimated fair value. The current Research & Development is $55.26 Mil. Tonix Pharmaceuticals Holding's overall GF Score™ is 41/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Tonix Pharmaceuticals Holding (TNXP), the current Research & Development is $55.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tonix Pharmaceuticals Holding (TNXP) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of $13.11 is trading 649.1% above its estimated GF Value™ of $1.75. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for TNXP:

  • Research & Development: $55.26 Mil
  • GF Value™: $1.75 vs. price of $13.11 (649.1% above fair value)
  • GF Score™: 41/100 with 2 warning signs

No single metric tells the full story. See the TNXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tonix Pharmaceuticals Holding Business Description

Other Exchanges TPM0:Germany
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
41GF Score

Get the complete analysis for TNXP

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.11
Price
$1.75
GF Value